Replacing Pseudoephedrine Easier Said Than Done, OTC Firms Find
This article was originally published in The Tan Sheet
Reformulating pseudoephedrine products has posed a greater challenge than expected for a number of firms, as passage of a federal bill restricting sale of the ingredient looms
You may also be interested in...
Joseph Papa brings 30 years of experience in healthcare and specialty generic pharmaceutical industries to his new position as president and CEO of Perrigo, the private-label manufacturer announced Sept. 11
Phenylephrine taken at the FDA-approved dose of 10 mg is "unlikely to provide relief of nasal congestion" and is less efficacious than pseudoephedrine, according to a letter to the editor in the July Journal of Allergy & Clinical Immunology.
Ads for reformulated Sine-Off cold and sinus products are scripted to position the brand as an active contributor to the nation's fight against methamphetamine abuse